スポンサーリンク
Department Of Molecular-targeting Cancer Prevention Department Of Medicine Graduate School Of Medica | 論文
- Monosomies 7p and 12p and FLT3 internal tandem duplication : possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution
- Histone Deacetylase Inhibitors : Promising Agents for 'Gene-Regulating Chemoprevention' and 'Molecular-Targeting Prevention' of Cancer
- INK4 Family : A Promising Target for 'Gene-Regulating Chemoprevention' and 'Molecular-Targeting Prevention' of Cancer
- Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease
- Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells
- Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis
- Identification of JTP-70902, a p15^-inductive compound, as a novel MEK1/2 inhibitor
- Inhibitory Effects of Cancer Cell Proliferation by Novel Histone Deacetylase Inhibitors Involve p21/WAF1 Induction and G_2/M Arrest(Medicinal Chemistry)
- Cell Cycle-dependent Modulation of Promoter Activities of RB and WAF1/Cip1 Genes
- Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells
- Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma : a single institute experience
- Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma : the collaborative study at six institutes in Kyoto and Osaka
- "Combination-oriented molecular-targeting prevention" of cancer : a model involving the combination of TRAIL and a DR5 inducer
- Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma